Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of salt and protein regulation on aquaresis during tolvaptan treatment in ADPKD
NL-OMON50000Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD) (4 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change in 24-hour urine volume. Started Sep 2020; status: active, not recruiting.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON50000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50000.